Nventa wins patent challenge for HPV drug patent

This patent, which allows exclusively through 2018, covers compositions of fusion proteins comprised of a human papillomavirus (HPV) antigen fused to a heat shock protein, as well as DNA encoding such fusion proteins.

This decision dismisses an appeal announced on January 30, 2006, and upholds the European Patent Office opposition division’s favorable decision of October 2005.

Gregory McKee, president and CEO of Nventa, said: “This favorable ruling reaffirms the strength of our intellectual property portfolio and reinforces an important composition-of-matter patent covering our lead product candidate, HspE7, and other future therapeutics for HPV-related diseases and cancer.”